Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 53

1.

Commentary: Questioning the HIV-AIDS Hypothesis: 30 Years of Dissent.

Karetnikov A.

Front Public Health. 2015 Aug 7;3:193. doi: 10.3389/fpubh.2015.00193. eCollection 2015. No abstract available.

2.

The need for treatment interruption studies and biomarker identification in the search for an HIV cure.

Li JZ, Smith DM, Mellors JW.

AIDS. 2015 Jul 31;29(12):1429-32. doi: 10.1097/QAD.0000000000000658. No abstract available.

3.

Clinical and demographic factors associated with low viral load in early untreated HIV infection in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial.

Law MG, Achhra A, Deeks SG, Gazzard B, Migueles SA, Novak RM, Ristola M; International Network for Strategic Initiatives in Global HIV Trials (INSIGHT) START Study Group.

HIV Med. 2015 Apr;16 Suppl 1:37-45. doi: 10.1111/hiv.12232.

4.

National trends in hospitalization and mortality rates for patients with HIV, HCV, or HIV/HCV coinfection from 1996-2010 in the United States: a cross-sectional study.

Oramasionwu CU, Toliver JC, Johnson TL, Moore HN, Frei CR.

BMC Infect Dis. 2014 Oct 10;14:536. doi: 10.1186/1471-2334-14-536.

5.

Differences in outpatient care and treatment utilization for patients with HIV/HCV coinfection, HIV, and HCV monoinfection, a cross-sectional study.

Johnson TL, Toliver JC, Mao L, Oramasionwu CU.

BMC Infect Dis. 2014 Apr 23;14:217. doi: 10.1186/1471-2334-14-217.

6.

Gender differences in oral lesions among persons with HIV disease in Southern India.

Rao UK, Ranganathan K, Kumarasamy N.

J Oral Maxillofac Pathol. 2012 Sep;16(3):388-94. doi: 10.4103/0973-029X.102492.

7.

Differences in HIV natural history among African and non-African seroconverters in Europe and seroconverters in sub-Saharan Africa.

Pantazis N, Morrison C, Amornkul PN, Lewden C, Salata RA, Minga A, Chipato T, Jaffe H, Lakhi S, Karita E, Porter K, Meyer L, Touloumi G; CASCADE Collaboration in EuroCoord and ANRS 1220 Primo-CI Study Group.

PLoS One. 2012;7(3):e32369. doi: 10.1371/journal.pone.0032369. Epub 2012 Mar 6.

8.
9.

Exploiting the anti-HIV-1 activity of acyclovir: suppression of primary and drug-resistant HIV isolates and potentiation of the activity by ribavirin.

Vanpouille C, Lisco A, Introini A, Grivel JC, Munawwar A, Merbah M, Schinazi RF, Derudas M, McGuigan C, Balzarini J, Margolis L.

Antimicrob Agents Chemother. 2012 May;56(5):2604-11. doi: 10.1128/AAC.05986-11. Epub 2012 Feb 6.

10.

Cumulative viral load and virologic decay patterns after antiretroviral therapy in HIV-infected subjects influence CD4 recovery and AIDS.

Marconi VC, Grandits G, Okulicz JF, Wortmann G, Ganesan A, Crum-Cianflone N, Polis M, Landrum M, Dolan MJ, Ahuja SK, Agan B, Kulkarni H; Infectious Disease Clinical Research Program (IDCRP) HIV Working Group.

PLoS One. 2011;6(5):e17956. doi: 10.1371/journal.pone.0017956. Epub 2011 May 20.

11.

Modification of the Abbott RealTime assay for detection of HIV-1 plasma RNA viral loads less than one copy per milliliter.

Yukl SA, Li P, Fujimoto K, Lampiris H, Lu CM, Hare CB, Deeks SG, Liegler T, Pandori M, Havlir DV, Wong JK.

J Virol Methods. 2011 Aug;175(2):261-5. doi: 10.1016/j.jviromet.2011.04.015. Epub 2011 Apr 22.

12.

Cost ramifications of increased reporting of detectable plasma HIV-1 RNA levels by the Roche COBAS AmpliPrep/COBAS TaqMan HIV-1 version 1.0 viral load test.

Willig JH, Nevin CR, Raper JL, Saag MS, Mugavero MJ, Willig AL, Burkhardt JH, Schumacher JE, Johnson VA.

J Acquir Immune Defic Syndr. 2010 Aug;54(4):442-4. doi: 10.1097/QAI.0b013e3181d01d1d. No abstract available.

13.

Daily acyclovir for HIV-1 disease progression in people dually infected with HIV-1 and herpes simplex virus type 2: a randomised placebo-controlled trial.

Lingappa JR, Baeten JM, Wald A, Hughes JP, Thomas KK, Mujugira A, Mugo N, Bukusi EA, Cohen CR, Katabira E, Ronald A, Kiarie J, Farquhar C, Stewart GJ, Makhema J, Essex M, Were E, Fife KH, de Bruyn G, Gray GE, McIntyre JA, Manongi R, Kapiga S, Coetzee D, Allen S, Inambao M, Kayitenkore K, Karita E, Kanweka W, Delany S, Rees H, Vwalika B, Magaret AS, Wang RS, Kidoguchi L, Barnes L, Ridzon R, Corey L, Celum C; Partners in Prevention HSV/HIV Transmission Study Team.

Lancet. 2010 Mar 6;375(9717):824-33. doi: 10.1016/S0140-6736(09)62038-9. Epub 2010 Feb 12.

14.

Defining treatment failure in resource-rich settings.

Aldous JL, Haubrich RH.

Curr Opin HIV AIDS. 2009 Nov;4(6):459-66. doi: 10.1097/COH.0b013e328331dea5. Review.

15.

Sex differences in the Toll-like receptor-mediated response of plasmacytoid dendritic cells to HIV-1.

Meier A, Chang JJ, Chan ES, Pollard RB, Sidhu HK, Kulkarni S, Wen TF, Lindsay RJ, Orellana L, Mildvan D, Bazner S, Streeck H, Alter G, Lifson JD, Carrington M, Bosch RJ, Robbins GK, Altfeld M.

Nat Med. 2009 Aug;15(8):955-9. doi: 10.1038/nm.2004. Epub 2009 Jul 13.

16.

Envelope coreceptor tropism, drug resistance, and viral evolution among subtype C HIV-1-infected individuals receiving nonsuppressive antiretroviral therapy.

Kassaye S, Johnston E, McColgan B, Kantor R, Zijenah L, Katzenstein D.

J Acquir Immune Defic Syndr. 2009 Jan 1;50(1):9-18. doi: 10.1097/QAI.0b013e31818ffdff.

17.

Herpes simplex virus (HSV)-suppressive therapy decreases plasma and genital HIV-1 levels in HSV-2/HIV-1 coinfected women: a randomized, placebo-controlled, cross-over trial.

Baeten JM, Strick LB, Lucchetti A, Whittington WL, Sanchez J, Coombs RW, Magaret A, Wald A, Corey L, Celum C.

J Infect Dis. 2008 Dec 15;198(12):1804-8. doi: 10.1086/593214.

18.

Cost-effectiveness of HIV screening in patients older than 55 years of age.

Sanders GD, Bayoumi AM, Holodniy M, Owens DK.

Ann Intern Med. 2008 Jun 17;148(12):889-903.

19.
20.
Items per page

Supplemental Content

Write to the Help Desk